May 13, 2026: Goldline Pharmaceutical Limited has opened its SME IPO 2026 for subscription on May 12, 2026, entering India’s active primary market at a time when pharmaceutical and healthcare-related public issues are witnessing rising investor attention.
Author: Aadarsh Patel | EQMint | IPO News
The IPO will remain open for bidding till May 14, 2026, while the company is expected to list on the BSE SME platform on May 19, 2026.
Goldline Pharmaceutical IPO Key Details
Here are the major IPO details investors should know:
- IPO Opening Date: May 12, 2026
- IPO Closing Date: May 14, 2026
- Price Band: ₹41 to ₹43 per share
- Face Value: ₹10 per equity share
- Issue Size: ₹11.61 crore
- Issue Type: Book Built Issue
- Fresh Issue: 27 lakh equity shares
- Listing Exchange: BSE SME
- Lot Size: 3,000 shares
- Minimum Retail Investment: Around ₹2.58 lakh for 2 lots at upper price band
- Allotment Date: May 15, 2026
- Listing Date: May 19, 2026
GMP Signals Strong Grey Market Interest
One of the biggest talking points around the IPO is its strong Goldline Pharmaceutical GMP.
According to market trackers, Goldline Pharmaceutical IPO GMP is currently around ₹16–₹17 per share. That indicates an estimated listing premium of nearly 37–40% over the upper issue price of ₹43.
The GMP has remained relatively stable during the subscription period, reflecting positive unofficial market sentiment around the issue.
However, investors should remember that GMP is unofficial and can change rapidly depending on subscription demand and market conditions.
About Goldline Pharmaceutical
Goldline Pharmaceutical is a Nagpur-based pharmaceutical marketing company operating under an asset-light business model.
Instead of manufacturing medicines directly, the company works through third-party manufacturing arrangements while focusing on:
- branding
- pharmaceutical marketing
- distribution
- product positioning
The company currently works with:
- 15 manufacturing partners
- 8 distributors
across different pharmaceutical segments.
Financial Performance
The company has shown strong financial growth in recent years.
According to available IPO data:
- FY25 revenue stood at around ₹28.06 crore
- PAT increased to ₹2.83 crore
- ROE remained above 27%
The IPO is priced at nearly 10.48x earnings at the upper price band, which some analysts believe is relatively reasonable compared to sector valuations.
What Will IPO Funds Be Used For?
The company plans to utilise the fresh issue proceeds for:
- working capital requirements
- business expansion
- general corporate purposes
The IPO is entirely a fresh issue with no Offer For Sale (OFS) component.
Risks Investors Should Track
Despite the strong GMP, investors should still watch certain risk factors carefully.
Some major concerns include:
- dependence on third-party manufacturers
- regional concentration
- relatively small scale of operations
- distributor dependency
- SME platform liquidity risks
SME IPOs can witness sharp volatility after listing, making risk management extremely important for retail investors.
Final Take
Goldline Pharmaceutical IPO has quickly emerged as one of the most discussed SME IPOs currently open in the market due to:
- strong GMP
- pharma sector interest
- reasonable valuation
- growing financial performance
The company’s asset-light pharma marketing model and improving profitability are attracting investor attention.
But like all SME IPOs, investors should focus not only on listing gains but also on business quality, scalability and long-term sustainability before applying.
For more upcoming IPOs India visit IPO News
For more such information visit EQMint
Join our Whatsapp channel for timely updates: Whatsapp
Disclaimer: This article is not an investment advice and is for educational purpose only.
